7 Facts About Antibody Drug Conjugates

By Brian Moloney, Director New Products & Innovation

Antibody drug conjugates (ADCs) have the potential to destroy cancerous cells without damaging healthy cells in the process, making them a growing field of interest in biopharmaceutics. Several ADCs are already successfully used in the treatment of myeloid leukemia or refractory metastatic breast cancer. Many others are in clinical trials and waiting for their FDA approval.

Learn the details behind different components and functions of ADCs and seven facts you probably didn't know yet about antibody drug conjugates and how they are advancing therapeutics.